Nurix Therapeutics, Inc. Common stock

Day range

$25.03 – $25.64

Open

$25.35

Prev close

$25.34

Volume

1.2M

Market cap

$2.77B

Shares out

109.25M

P/E

9.39

P/S

3.94

P/B

2.86

P/FCF

7.49

ROE

30.4%

ROA

24.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Quarterly earningsOct 13, 2026

  On October 12, 2026, Nurix Therapeutics, Inc. issued a press release announcing the Company's financial results for the fiscal quarter ended August 31, 2026.

• Clinical trial resultsJun 11, 2026

  Updated clinical data from the Phase 1a/1b study of the Company's novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The updated Phase 1a data included 48 patients with relapsed or refractory CLL/SLL with an objective response rate (ORR) of 83.0%, including two patients with complete response and 36 patients with partial response. Median progression-free survival was 22.1 months.

• Investor presentationJun 8, 2026

  On June 8, 2026, at 8:00 a.m. Eastern Time, Nurix will host a conference call and webcast to discuss the collaboration between Nurix and Roche. The live webcast, with an accompanying presentation, will be accessible under the Events and Presentations page in the Investors section of Nurix's website.

• Annual meeting resultsMay 15, 2026

  On May 15, 2026, Nurix Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders exclusively online via live webcast (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals. Each of the three nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026. The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.

• Public offeringMar 6, 2026

  On March 6, 2026, the Company and Piper Sandler entered into Amendment No. 3 to the Equity Distribution Agreement pursuant to which, from time to time, the Company may offer and sell through Piper Sandler, as sales agent, $413.65 million of shares of the Company's common stock, $0.001 par value per share (the 'Shares') pursuant to one or more 'at the market' offerings.

Days to cover

9.9

Short interest

17.66M

Avg volume

1.78M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
  neutralZacks Investment Research· Oct 22, 2026
• Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
  positiveZacks Investment Research· Oct 19, 2026
• Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
  neutralZacks Investment Research· Oct 12, 2026
• Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
  positiveZacks Investment Research· Oct 1, 2026
• AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
  negativeZacks Investment Research· Sep 21, 2026